Holen Sie sich die Stockscreener-App
3.01
3.98%
-0.13
Handel nachbörslich:
3.01
Immunitybio Inc Aktie (IBRX) Neueste Nachrichten
Why ImmunityBio Inc. (IBRX) Went Up Last Week? - Yahoo Finance
ImmunityBio to Host Investor Day - BioSpace
Is ImmunityBio, Inc. (NASDAQ:IBRX) The Top Penny Stock That Will Skyrocket? - Insider Monkey
Investor Alert: Wolfspeed, Driven Brands Holdings, Hasbro, - GlobeNewswire
Investor Alert: Wolfspeed, Driven Brands Holdings, Hasbro, and ImmunityBio: Johnson Fistel, PLLP Investigates - EIN News
ImmunityBio appoints Deloitte as new auditor By Investing.com - Investing.com South Africa
ImmunityBio appoints Deloitte as new auditor - Investing.com Australia
Drugmaker's $10.5M Deal In Investor FDA Approval Suit OK'd - Law360
ImmunityBio $10.5 Million Settlement Over Record Selloff Gets OK - Bloomberg Law News
From cancer vaccines to COPD treatments, these 10 companies are developing innovative medicines - Fast Company
ImmunityBio ($IBRX) Is Paying a $10.5M Settlement to Investors — Here’s How to Get Your Share - TradingView
H.C. Wainwright maintains $8 target for ImmunityBio stock By Investing.com - Investing.com Australia
H.C. Wainwright maintains $8 target for ImmunityBio stock - Investing.com
Recombinant BCG Vaccine Becomes Available in the U.S. - Precision Vaccinations
ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching - BioSpace
ImmunityBio Partner US Urology Begins Administering rBCG to Address Tice BCG Shortage - Marketscreener.com
ImmunityBio, Inc. (IBRX): Among the Stocks Under $10 With High Upside Potential - Insider Monkey
ImmunityBio (IBRX) Expected to Announce Earnings on Tuesday - Defense World
SBI Securities Co. Ltd. Buys New Position in ImmunityBio, Inc. (NASDAQ:IBRX) - Defense World
Q1 Earnings Forecast for ImmunityBio Issued By HC Wainwright - Defense World
Private Advisor Group LLC Cuts Stock Position in ImmunityBio, Inc. (NASDAQ:IBRX) - Defense World
HC Wainwright Begins Coverage on ImmunityBio (NASDAQ:IBRX) - Defense World
ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum - Seeking Alpha
H.C. Wainwright sets $8 target for ImmunityBio stock, rates Buy By Investing.com - Investing.com South Africa
ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug - Benzinga
This Tourmaline Bio Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Benzinga India
H.C. Wainwright sets $8 target for ImmunityBio stock, rates Buy - Investing.com
HC Wainwright Initiates Coverage on ImmunityBio With Buy Rating, $8 Price Target -March 06, 2025 at 07:26 am EST - Marketscreener.com
HC Wainwright & Co. Initiates Coverage of ImmunityBio (IBRX) with Buy Recommendation - Nasdaq
H.C. Wainwright starts coverage of ImmunityBio with 'buy' rating - TradingView
Earnings Update: ImmunityBio, Inc. (NASDAQ:IBRX) Just Reported Its Full-Year Results And Analysts Are Updating Their Forecasts - Simply Wall St
New York State Common Retirement Fund Grows Position in ImmunityBio, Inc. (NASDAQ:IBRX) - Defense World
ImmunityBio (NASDAQ:IBRX) Trading Up 6.8% Following Strong Earnings - Defense World
Why ImmunityBio Inc. (IBRX) Crashed on Monday - MSN
ImmunityBio Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
ImmunityBio: Q4 Earnings Snapshot - Barchart
ImmunityBio, Inc. (NASDAQ:IBRX) Shares Bought by Handelsbanken Fonder AB - Defense World
ImmunityBio’s Sales Surge Amid Strategic Advances - TipRanks
ImmunityBio stock rises on Q4 earnings beat, revenue growth - Investing.com India
Why ImmunityBio, Inc. (IBRX) Soared on Friday - MSN
ImmunityBio stock rises on Q4 earnings beat, revenue growth By Investing.com - Investing.com South Africa
Immunitybio Inc earnings beat by $0.08, revenue topped estimates - Investing.com South Africa
ImmunityBio (IBRX) Reports Q4 Loss, Misses Revenue Estimates - MSN
ImmunityBio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
1.06%
1.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):